BioCentury | Mar 11, 2021
Regulation

Tivozanib, at last, is Aveo’s first approved drug in the U.S.

...he was at Genetics Institute Inc. (now part of Wyeth), where he completed licenses with Chugai Pharmaceutical Co. Ltd....
BioCentury | Feb 27, 2021
Distillery Therapeutics

Trastuzumab-RNA polymerase inhibitor conjugate for breast cancer with low HER2 expression

...alone.The Genentech Inc. unit of Roche (SIX:ROG; OTCQX:RHHBY) and Chugai Pharmaceutical Co. Ltd. (Tokyo:4519) market Kadcyla for breast cancer. Genentech, Chugai...
BioCentury | Feb 26, 2021
Distillery Therapeutics

Zelboraf-based PROTAC for melanoma, lung cancer expressing BRAF mutations

...include testing the PROTAC in preclinical models of hairy cell leukemia.Daiichi Sankyo Co. Ltd. (Tokyo:4568), Chugai Pharmaceutical Co. Ltd....
BioCentury | Feb 5, 2021
Management Tracks

Chugai names Okuda CEO; plus Astellas promotes Barretto-Ko to CBO, Goto to CSO and updates from Merck KGaA, Scholar Rock, Berkeley Lights, Catamaran and more

...By BioCentury Staff Chugai Pharmaceutical Co. Ltd. (Tokyo:4519) promoted Osamu Okuda to CEO from president and COO, succeeding Tatsuro Kosaka...
...CEO from president and COO, succeeding Tatsuro Kosaka who will remain chairman. Okuda, who joined Chugai...
...GM of corporate planning and co-head of life-cycle management. The move is effective March 23; Chugai...
BioCentury | Feb 1, 2021
Deals

Seeing potential blockbusters, Horizon buys AstraZeneca spinout Viela for more than $3B

...C5 inhibitor Soliris eculizumab from Alexion Pharmaceuticals Inc. (NASDAQ:ALXN) and anti-IL-6R mAb Enspryng satralizumab-mwge from Chugai...
BioCentury | Jun 30, 2020
Regulation

Data Bytes: Drug approvals in Japan

...Onbrize, Onbrez Breezhaler, Onbrez Inhalation Capsules, indacaterol (QAB149) GlaxoSmithKline plc Novo Nordisk A/S Mitsubishi Tanabe Pharma Corp. Akebia Therapeutics Inc. Chugai Pharmaceutical Co. Ltd. Novartis...
BioCentury | Apr 3, 2020
Distillery Therapeutics

Depletion of the mitochondrial chaperone HspA9 for BRAF-mutant melanoma

...including a Zelboraf-resistant model, the HspA9 inhibitor inhibited tumor growth. Daiichi Sankyo Co. Ltd. (Tokyo:4568), Chugai Pharmaceutical Co. Ltd....
BioCentury | Feb 28, 2020
Finance

Verastem raises $100M, plots path forward with targeted cancer combo

...it has cash to fund operations into 4Q21. Verastem acquired worldwide rights to VS-6766 from Chugai Pharmaceutical Co. Ltd....
...time, Verastem said it would explore partnering strategies for the therapy, previously known as CH5126766. Chugai...
BioCentury | Jan 25, 2020
Product Development

A milestone year for Roche’s CNS gambit could kick off its plan for the decade

...Satralizumab is one of only two late-stage compounds produced internally -- it was developed by Chugai Pharmaceutical Co. Ltd....
BioCentury | Dec 20, 2019
Product Development

Pharma spinouts: a snapshot of where and how pharmas spin out their assets

...retains only three early clinical-stage candidates, two of which are being developed by its affiliate Chugai Pharmaceutical Co. Ltd....
Items per page:
1 - 10 of 1176
BioCentury | Mar 11, 2021
Regulation

Tivozanib, at last, is Aveo’s first approved drug in the U.S.

...he was at Genetics Institute Inc. (now part of Wyeth), where he completed licenses with Chugai Pharmaceutical Co. Ltd....
BioCentury | Feb 27, 2021
Distillery Therapeutics

Trastuzumab-RNA polymerase inhibitor conjugate for breast cancer with low HER2 expression

...alone.The Genentech Inc. unit of Roche (SIX:ROG; OTCQX:RHHBY) and Chugai Pharmaceutical Co. Ltd. (Tokyo:4519) market Kadcyla for breast cancer. Genentech, Chugai...
BioCentury | Feb 26, 2021
Distillery Therapeutics

Zelboraf-based PROTAC for melanoma, lung cancer expressing BRAF mutations

...include testing the PROTAC in preclinical models of hairy cell leukemia.Daiichi Sankyo Co. Ltd. (Tokyo:4568), Chugai Pharmaceutical Co. Ltd....
BioCentury | Feb 5, 2021
Management Tracks

Chugai names Okuda CEO; plus Astellas promotes Barretto-Ko to CBO, Goto to CSO and updates from Merck KGaA, Scholar Rock, Berkeley Lights, Catamaran and more

...By BioCentury Staff Chugai Pharmaceutical Co. Ltd. (Tokyo:4519) promoted Osamu Okuda to CEO from president and COO, succeeding Tatsuro Kosaka...
...CEO from president and COO, succeeding Tatsuro Kosaka who will remain chairman. Okuda, who joined Chugai...
...GM of corporate planning and co-head of life-cycle management. The move is effective March 23; Chugai...
BioCentury | Feb 1, 2021
Deals

Seeing potential blockbusters, Horizon buys AstraZeneca spinout Viela for more than $3B

...C5 inhibitor Soliris eculizumab from Alexion Pharmaceuticals Inc. (NASDAQ:ALXN) and anti-IL-6R mAb Enspryng satralizumab-mwge from Chugai...
BioCentury | Jun 30, 2020
Regulation

Data Bytes: Drug approvals in Japan

...Onbrize, Onbrez Breezhaler, Onbrez Inhalation Capsules, indacaterol (QAB149) GlaxoSmithKline plc Novo Nordisk A/S Mitsubishi Tanabe Pharma Corp. Akebia Therapeutics Inc. Chugai Pharmaceutical Co. Ltd. Novartis...
BioCentury | Apr 3, 2020
Distillery Therapeutics

Depletion of the mitochondrial chaperone HspA9 for BRAF-mutant melanoma

...including a Zelboraf-resistant model, the HspA9 inhibitor inhibited tumor growth. Daiichi Sankyo Co. Ltd. (Tokyo:4568), Chugai Pharmaceutical Co. Ltd....
BioCentury | Feb 28, 2020
Finance

Verastem raises $100M, plots path forward with targeted cancer combo

...it has cash to fund operations into 4Q21. Verastem acquired worldwide rights to VS-6766 from Chugai Pharmaceutical Co. Ltd....
...time, Verastem said it would explore partnering strategies for the therapy, previously known as CH5126766. Chugai...
BioCentury | Jan 25, 2020
Product Development

A milestone year for Roche’s CNS gambit could kick off its plan for the decade

...Satralizumab is one of only two late-stage compounds produced internally -- it was developed by Chugai Pharmaceutical Co. Ltd....
BioCentury | Dec 20, 2019
Product Development

Pharma spinouts: a snapshot of where and how pharmas spin out their assets

...retains only three early clinical-stage candidates, two of which are being developed by its affiliate Chugai Pharmaceutical Co. Ltd....
Items per page:
1 - 10 of 1176